Rimegepant is a medication used in this study to explore its effects on migraine headaches. It works by blocking a specific protein in the brain that is involved in the development of migraines. This protein is called the calcitonin gene-related peptide (CGRP) receptor. By blocking this receptor, rimegepant can help reduce the frequency and severity of migraine attacks. In this trial, researchers are looking at how rimegepant affects people with different body weights, specifically those who are lean and those who are obese, to see if weight influences the medication’s effectiveness in preventing migraines.

Obesity – Obesity is a condition characterized by excessive body fat accumulation that may negatively impact health. It develops when calorie intake consistently exceeds calorie expenditure, leading to an energy imbalance. Over time, this excess energy is stored as fat, resulting in increased body weight. The progression of obesity can lead to changes in body composition, including increased fat mass and altered distribution of body fat. As obesity progresses, it can affect various bodily systems, potentially leading to metabolic changes and increased strain on the cardiovascular system. The condition is often associated with other health issues, such as insulin resistance and inflammation.

Migraine – Migraine is a neurological disorder characterized by recurrent, often severe headaches, typically affecting one side of the head. The progression of a migraine attack can include a prodrome phase with early warning symptoms, followed by an aura phase in some individuals, which may involve visual disturbances. The headache phase is marked by intense, throbbing pain, often accompanied by nausea, vomiting, and sensitivity to light and sound. The attack can last from a few hours to several days. After the headache subsides, a postdrome phase may occur, where individuals feel drained or fatigued. Migraine attacks can vary in frequency and intensity, impacting daily activities and quality of life.